Mutations in the thyroid hormone transporter monocarboxylate transporter 8 (MCT8) prevent appropriate entry of thyroid hormones into brain cells during development and cause severe mental retardation in affected patients. The current treatment options are thyromimetic compounds that enter the brain independently of MCT8. Some MCT8-deficient patients (e.g., those carrying MCT8 delF501 ) will not be as severely affected as most others. We have shown that the MCT8 delF501 protein has decreased protein stability but important residual function once it reaches the plasma membrane. We were able to rescue protein expression and the function of MCT8 delF501 in a MadinDarby canine kidney cell model by application of the chemical chaperone sodium phenylbutyrate (NaPB), a drug that has been used to treat patients with cystic fibrosis and urea cycle defects for extended periods of time. In the present study, we have extended our previous study and report on the NaPB-dependent rescue of a series of other pathogenic MCT8 mutants associated with milder patient phenotypes. We show that NaPB can functionally rescue the expression and activities of Ser194Phe, Ser290Phe, Leu434Trp, Arg445Cys, Leu492Pro, and Leu568Pro mutations in MCT8 in a dose-dependent manner. The soy isoflavone genistein, a dietary supplement, which was effective in MCT8 delF501
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, was also effective in increasing the expression and transport of these MCT8 mutants; however, the effect size differed among mutants. Kinetic analyses revealed that the Michaelis constants of the mutants toward the primary substrate 3,3 0 ,5-triiodothyronine were not much different from the wild-type value, suggesting that these mutants are not impaired in their interaction with substrate but rather destabilized by the mutation and degraded. (Endocrinology 158: 678-691, 2017) M onocarboxylate transporter 8 (MCT8) is a transmembrane transporter for thyroid hormones, and mutations in MCT8 lead to severe X-linked mental retardation and muscle hypotonia (1) (2) (3) . This was first described as Allan-Herndon-Dudley syndrome (AHDS) in 1944 (4) . MCT8 facilitates the transport of biologically active 3,3 0 ,5-triiodothyronine (T 3 ), its prohormone 3,3 0 ,5,5 0 -tetraiodothyronine (T 4 ), the inactive reverse 3,3 0 ,5 0 -triiodothyronine (rT 3 ) and 3,3 0 -diiodothyronine (5, 6). The cognitive impairments found in MCT8-deficient patients are generally believed to be a consequence of the relative lack of thyroid hormones during embryonic development of the brain (7) (8) (9) (10) (11) (12) (13) . As a treatment of MCT8 deficiency, the T 3 metabolite 3,3 0 ,5-triiodothyroacetic acid (TRIAC) has been evaluated as an MCT8-independent T 3 receptor agonist. High doses of TRIAC normalized the brain phenotype of Mct8/organic anion transporting polypeptide (Oatp) 1c1 double knockout mice (14) . Currently, a clinical trial is underway to explore the TRIAC treatment of MCT8-deficient patients (ClinicalTrials.gov identifier, NCT02060474).
Although AHDS is characterized by cognitive impairment and developmental delays, some MCT8 patients will show milder symptoms than others (3, (15) (16) (17) (18) (19) (20) . Decreased protein stability of an otherwise functional protein might be an explanation for the milder phenotypes. We, and others, have shown that the expression and stability of MCT8 mutant proteins are cell-type specific (18, 21, 22) . We propose that the same might be true for human cell types, with some cells able to translocate a fraction of mutant MCT8 to the plasma membrane, and other cells might more effectively eliminate the mutant proteins.
A similar situation is found in cystic fibrosis (CF), a disease caused by inactivation of the CF transmembrane conductance regulator (CFTR). Most CF patients carry the same deletion of phenylalanine 508 that leads to intracellular retention and degradation of the misfolded protein (23) . The chemical chaperone, sodium phenylbutyrate (NaPB), has been used for the treatment of CF, because it stimulates translocation to the plasma membrane of the mutant CFTR protein, where it elicits some activity (24) (25) (26) (27) . More recently, specific compounds have been brought into clinical use to rescue mutant CFTR, including lumacaftor (28) . In general, chemical chaperones are small molecules that facilitate mutant protein folding by preventing protein aggregation or degradation (29) . We have applied the idea of chemical chaperone treatment to mutant MCT8 (30) . Deletion of phenylalanine 501 in MCT8 (MCT8 delF501 ) causes a milder form of AHDS (17) . MCT8 delF501 showed decreased protein stability in MadinDarby canine kidney (MDCK) 1 cells and Xenopus oocytes (30) , although its expression in human placental choriocarcinoma JEG3 cells was not reduced (17) . NaPB was able to substantially enhance expression and thyroid hormone transport activity of MCT8 delF501 in MDCK1 cells (30) . In the present report, we have expanded our earlier work and show that pathogenic MCT8 mutants that lead to milder forms of AHDS (i.e., Ser194Phe, Ser290Phe, Leu434Trp, Arg445Cys, Leu492Pro, and Leu568Pro) are generally responsive to NaPB in our in vitro cell models.
Materials and Methods

Cloning and stable transfection
Mutations were introduced into full-length MCT8 by sidedirected mutagenesis (QuikChange Lightning; Agilent Technologies, Santa Clara, CA). The primers used are summarized in Table 1 . Stable transfection of mutated MCT8 in MDCK1 cells and COS7 cells (fibroblast-like cell line from primate kidney) was performed as described previously (21, 30) . The MDCK1 cell model is an established model for the study of plasma membrane transporters, lack endogenous MCT8 expression, and show little background T 3 uptake activity (21) . To achieve stably transfected COS7 cells, they were cultured in Dulbecco's modified Eagle medium (DMEM)/F12 (1:1; Gibco, Thermo Fisher Scientific Life Sciences, Waltham, MA) plus 10% fetal calf serum (FCS; Gibco) plus 0.5% to 1% G418 (Biochrom, Cambridge, UK) for 1 week until most of the cells had died. Subsequently, the medium was changed to DMEM/F12 (1:1) plus 10% FCS plus 1% penicillin (5000 U/mL)/streptomycin (5000 mg/mL) until the cells had recovered. The cells were frozen and screened for expression as described previously (30) .
Cell culture and chaperone treatment
Stable transfected MDCK1 cells and COS7 cells were cultured in DMEM/F12 (1:1) plus 10% FCS plus 1% penicillin/ streptomycin and treated for 48 hours for MDCK1 and 24 hours for COS7 cells, with exogenous chaperones, as described previously (30) . Human fibroblasts were either cultured in DMEM/F12 (1:1) plus 10% FCS plus 1% penicillin/streptomycin or minimal essential medium (MEM; Gibco) plus 10% FCS plus 1% penicillin/streptomycin plus 1% MEM vitamins (Gibco) plus 1% sodium pyruvate solution (100 mM; Invitrogen, Thermo Fisher Scientific Life Sciences) plus 0.2% uridine aqueous solution (25 mg/mL; Invitrogen) plus 1% MEM nonessential amino acids (1003; Thermo Fisher Scientific Life Sciences) plus 1% L-glutamax (1003; Gibco) and treated with chaperones for 48 hours, with a change of the medium after 24 hours. NaPB was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and directly dissolved in medium at a final concentration of 16 mM. NaPB is not only used as an exogenous chaperone but has also been described as an inhibitor of histone deacetylases and proliferation (31, 32) . Thus, high concentrations of NaPB led to increased cell death of MDCK1 cells and COS7 cells in culture. The NaPB concentrations chosen for the treatment of cells that underwent radioactive uptake assay have been chosen from the lowest concentration (2 to 4 mM NaPB) that showed a good response in western blot. Genistein was obtained from SigmaAldrich (St. Louis, MO) and dissolved in dimethyl sulfoxide at a final concentration of 100 mM. The genistein concentrations used for the treatment of cells that underwent radioactive uptake assay were chosen from the concentration (15 to 25 mM genistein) that showed the best response in western blot.
Western blotting and surface biotinylation
Pellets from stably expressing MDCK1 cells and COS7 cells were harvested from 6-well plates and lysed in 75 mL homogenization buffer (250 mM saccharose, 20 mM HEPES, 1 mM EDTA in distilled water, pH 7.4) with 1 mM dithiothreitol. Pellets from fibroblasts were harvested from 100-mm plates and lysed in 60 mL of homogenization buffer with 1 mM dithiothreitol. Twenty-five micrograms of whole cell lysates were separated on 10% sodium dodecyl sulfate polyacrylamide gels, transferred on nitrocellulose membranes, and probed with antibodies against MCT8 (resource research identifier, AB_611613) and b-actin (resource research identifier, AB_262011; Table 2 ). Surface biotinylation of stably transfected MDCK1 cells was performed as described previously (30) . Fifteen microliters of biotinylated protein were used for western blot analysis, as described previously.
Radioactive uptake assays
Three days before the experiments, 50,000 to 140,000 cells of stably transfected MDCK1 and COS7 cells were seeded into 12-well plates. The chaperone treatment of MDCK1 cells started 1 day after seeding for 48 hours, with a change of the medium after 24 hours. The chaperone treatment of COS7 cells started for 24 hours once the cells had reached confluence. The COS7 cells did not tolerate a longer treatment period. Fibroblasts were seeded into 24-well plates (1000 cells per well), and chaperone treatment was started once the cells had reached 95% confluence. The fibroblasts were treated with NaPB for 48 hours, with a change of the medium after 24 hours.
Purification of iodine-125 ( 125 I)-T 3 (PerkinElmer, Shelton, CT) from iodide ions was performed as described previously (30) . Next, 2 nM 125 I-T 3 plus 10 nM T 3 (Sigma-Aldrich) diluted in DMEM/F12 (1:1) was used for the time course (1-to 30-minute) and endpoint (10-minute) experiments. The cells were washed, lysed, and measured as described previously (30) .
For the determination of the Michaelis constants (K m ), the cells were incubated with increasing concentrations of T 3 (0.5 to 12 mM) for 3 to 5 minutes.
Inhibition studies
Silychristin (SC), a specific inhibitor of MCT8 (33), was purchased from PhytoLabs (Vestenbergsgreuth, Germany) and dissolved in dimethyl sulfoxide at a final concentration of 40 mM. Bromsulphthalein (BSP) was obtained from SigmaAldrich and dissolved in water at a final concentration of 60 mM. We used 10 mM SC and 1 mM BSP for the inhibition studies. Both compounds were directly given to the cells, together with nonradioactive T 3 diluted in DMEM/F12 (1:1).
Results
NaPB and genistein increase the transport activity of MCT8
L568P
The substitution of leucine to proline at position 568 in MCT8 is associated with a milder phenotype of AHDS (3, 34 All 3 mutants dose dependently responded to increasing concentrations of NaPB and genistein with increased protein expression (Supplemental Fig. 3 ). NaPB, but not genistein, enhanced T 3 transport activity [ Fig. 3 We used increasing concentrations of T 3 , ranging from 0.5 to 12 mM, to determine the K m values. The incubation times were determined from the results of the time-course experiments (Supplemental Fig. 2 ) and chosen from the linear range. Because genistein did not affect the T 3 transport activity of mutant proteins, we exclusively treated the cells with NaPB. The K m values of treated and untreated MCT8 L434W , MCT8
R445C
, and MCT8 L492P did not differ from wild-type MCT8 (Fig. 4) . The K m values are summarized in Table 3 . press.endocrine.org/journal/endo
Mutants carrying serine to phenylalanine substitutions at positions 194 and 290 respond to higher concentrations of NaPB A mutation of serine to phenylalanine substitutes a small hydrophilic by a bulky hydrophobic amino acid. The changes in chemical properties possibly lead to a reduction in transport activity and/or a decrease in protein stability. Thus, we tested the effects of exogenous chaperones on both pathogenic mutations. Table 3 .
The effect of chaperone treatment on human MCT8 expressed in other cell types To investigate the effect of chaperone treatment on human MCT8 expressed in other cell types, we stably transfected fibroblast-like COS7 cells with pathogenic MCT8 mutants. Untransfected COS7 cells showed high background 125 I-T 3 uptake activity [ Fig. 7(A) , Upper], probably owing to the expression of endogenous thyroid hormone transporters. Expression of MCT8 in stably transfected COS7 cells unexpectedly decreased T 3 uptake compared with untransfected cells (see Discussion). Nevertheless, most of the pathogenic MCT8 mutants readily responded to 2 mM NaPB treatment with significantly increased protein expression [ Fig. 7(A) , Lower]. Also, 15 mM genistein did not affect MCT8 expression in this cell system. 125 I-T 3 uptake was measured in all MCT8-transfected COS7 cell lines but was not informative because of the high background uptake activity [ Fig. 7(A) ].
Primary human skin fibroblasts showed low 125 I-T 3 uptake activity compared with fibroblast-like COS7 cells [ Fig. 7(B) , Upper]. The treatment of fibroblasts with 2 concentrations of NaPB did not change the expression pattern of endogenously expressed MCT8 [ Fig. 7(B) , Lower]. Fibroblasts showed a slower growth rate when cultured in DMEM/F12 than in MEM. A slower growth rate should be beneficial for proper membrane protein folding and membrane insertion but had only a modest effect on endogenous MCT8 expression and function [ Fig. 7(B) ]. These experiments were performed with fibroblasts from 2 unrelated donors and 1 culture was tested at passages 6 and 16 without substantially different results [ Fig. 7(B , and MCT8 S194F . The NaPB-mediated rescue of T 3 transport activity in MDCK1 cells ranged from 23% to 67% (Table 4) . Application of the recently described MCT8-specific inhibitor SC abolished the increase, suggesting that MCT8-mediated T 3 transport was specifically rescued (33) . Mutant MCT8 expression and function were also tested for chaperone response in COS7 cells. These cells showed a high background uptake of T 3 , probably owing to the expression of endogenous thyroid hormone transporters whose expression has been previously reported for related COS1 cells (35) . The additional stable expression of human MCT8 led to a reduction of T 3 transport, suggesting increased efflux.
Such increased efflux on transfection with a transporter is a well-known phenomenon if this transporter acts as an active exporter and was recently observed in COS1 cells (36) .
NaPB has been used for the treatment of CF. It acts as an exogenous chaperone and helps the unstable CFTR protein to fold properly (24, 26, 27) . This principle has been developed further, leading to lumacaftor, a drug specifically designed to increase the membrane expression of CFTR delF508 , which has recently been evaluated in patients (28) . Although NaPB is not specifically designed to address MCT8 mutations, long-term application of NaPB in children with urea cycle defects has suggested that NaPB might also represent a safe treatment option for a subset of AHDS patients.
The mutation of leucine residues probably disturbs the correct insertion of the transmembrane protein into the plasma membrane
Patients with the pathogenic mutation MCT8 L568P were the first patients described with AHDS in 1944 (4). They show severe mental retardation but achieve the ability to walk with difficulty and to speak some words at 2 to 3 years of age (3, 15) . MCT8 L568P shows residual T 3 uptake activity of 53% of wild-type MCT8 in MDCK1 cells and a strong reduction of MCT8 at the cell surface. Residual uptake activity was previously described (34) and is probably responsible for the milder symptoms of the disease, because the uptake of thyroid hormones into different cells of the body is not completely abolished. NaPB and genistein could further increase surface expression and T 3 uptake into MCT8 L568P -expressing MDCK1 cells #76% and #99%, respectively ( (3, 16, 19) . Residual T 3 uptake activity was reported for both mutations in JEG3 cells (18, 19, 34) and was also found in MDCK1 cells (Table 4) . NaPB and genistein rescued mutant MCT8 protein expression at the cell surface; however, only NaPB increased the residual activity of MCT8
L434W
and MCT8 L492P by 30% to 45%. The K m values of both NaPB-rescued proteins were in the range of those of wildtype MCT8, indicating a similar affinity toward T 3 .
Figure 7(C) shows the localization of all 3 mutated leucines in the homology model of MCT8 (6, 37) . The data suggest the interaction of the leucine side chains with phospholipids of the plasma membrane. A mutation of leucine to proline eliminates the possibility to form a helical hydrogen bond within the transmembrane helix. The leucine to tryptophan mutation does not change the chemical properties of the residue but replaces a branched amino acid with a bulky aromatic amino acid. The mutations of the leucine residues probably result in structural changes within the transmembrane helices, thus leading to decreased protein stability.
The expression levels of leucine mutants differ among each other compared with wild-type MCT8 in MDCK1 cells. MCT8
L568P shows higher protein expression in whole cell lysates, but the expression of MCT8 L434W and MCT8 L492P is only moderate. One explanation could be that Leu568 is located within the last transmembrane helix and thus would not interfere with the assembly of protein C-terminal to the mutation. However, examples have been reported depicting different consequences with leucine mutations. A leucine to proline substitution at position 127 in the P-type ATP8B1 (adenosine triphosphatase member 8B1) did not affect the expression nor the translocation of the membrane protein to the cell surface, while the nonactive site mutations L22P and L408P of the membraneassociated retinoid isomerase RPE65 led to rapid proteasomal protein degradation (38, 39) . Missense mutations of ATP8B1 and RPE65 have both been tested for a response to NaPB (38, 39). The chemical chaperone was able to rescue the protein expression and function of several mutants. The molecular mechanism behind the NaPB action remains, however, unclear and might also involve interactions with protein quality control pathways. Genistein was able to rescue MCT8 delF501 protein expression and function (30) . It also worked for MCT8 L568P but not for the other missense mutations tested in our study. Genistein is known as an inhibitor of MCT8 and might function as a pharmacological chaperone (30) . However, its mode of action remains disputed, and it might also alter protein-lipid interactions (40) , which might, in turn, affect the protein quality control machinery. To date, NaPB has been assumed to act as a press.endocrine.org/journal/endochemical chaperone that is reported to modulate components of the quality control system of a cell (41) . Thus, the action of NaPB on protein expression would be indirect. However, both NaPB and genistein rescue MCT8 mutant protein expression at the cell surface, although only NaPB leads to functional recovery. This observation raises the possibility that NaPB might exert a direct effect on mutant MCT8. The MCT8 homology model suggests the localization of Arg445, Ser194, and Ser290 in close structural proximity to the putative substrate channel Arg445 shows a strong conservation among all MCT members (6, 42) . In addition, our MCT8 homology model predicted the formation of a salt bridge between Arg445 and Asp498 that might be involved in the initiation of the protein's conformational change during the transport process (6) . Finally, the importance of the residue became clear when the pathogenic R445C mutation was identified (18) . Patients with this mutation are capable of walking with help and are able to pronounce words by 4 years of age (18) . In several studies, JEG3 cells transiently transfected with MCT8 R445C showed moderate residual T 3 uptake activity of 10% to 15% (18, 42) . The residual activity of 81% found in MDCK1 is even higher (Table 4 ) and can be enhanced to 127% by NaPB, and MCT8 R445C -mediated T 3 transport in patientderived fibroblasts is completely abolished by the pathogenic mutation (18) . Several examples of arginine to cysteine mutations have been reported that also respond to chemical chaperone treatment. Arg1128Cys in the ABCB11 protein encoding for a bile salt export pump prevents its targeting to the cell surface by retaining the mutant protein in the endoplasmic reticulum, an effect that was partially corrected by NaPB (43) . NaPB also increased the solubility of aggregates formed by the lens structural protein gD-crystallin with arginine to cysteine mutations at positions 15 and 61 (44) .
The affinity of NaPB-treated and -untreated protein toward T 3 did not differ from that of wild-type MCT8, because the K m values do not show substantial differences in MDCK1 cells (Table 3) . A previous study by Groeneweg et al. (42) made clear that the exchange of the basic arginine to the short hydrophobic alanine prevents T 3 uptake and the mutation to the shorter, but also basic, lysine only leads to a reduction in transport activity. Furthermore, the reduced, but not completely abolished, T 3 transport of MCT8 R445C in MDCK1 cells rather suggests the formation of hydrogen bonds that are crucial for transport function because cysteine is an uncharged but hydrophilic amino acid. The predicted localization of Arg445 within the potential transport channel suggests a direct interaction with MCT8 substrates [ Fig. 7(D) ].
Both serine to phenylalanine mutations result in milder symptoms of AHDS. Patients with the mutations are able to pronounce some words. However, in contrast to patients with MCT8 S290F mutations, patients with MCT8 S194F do not achieve the ability to walk (3, 20) .
Residual T 3 uptake activity was found in JEG3 cells for MCT8 S194F but not for MCT8 S290F (18, 20, 34) . As previously reported, MCT8 S194F completely abolished T 3 uptake (21) and MCT8 S290F showed moderate residual uptake activity in MDCK1 cells (Table 4) . As stated, MCT8 R445C showed an opposite pattern of residual activity, with low transport activity in JEG3 cells and high uptake in MDCK1 cells. The differences in residual transport activity might be related to the different press.endocrine.org/journal/endo composition up of the cellular protein quality control systems. Thus, the complete degradation of unstable MCT8 mutant protein could occur in 1 cell type, with other cell types showing moderate expression of the mutant protein at the cell surface. In turn, this would explain the milder symptoms of AHDS found in some MCT8 patients.
NaPB increased the T 3 uptake of both serine mutants (Table 4) without significantly altering the K m values of the treated mutant protein toward T 3 ( Table 3 ). The mutation of hydrophilic serine to hydrophobic phenylalanine might disturb the formation of hydrogen bonds within the protein. However, Armour et al. (20) showed that MCT8 S290A in JEG3 cells did not lose the ability to transport T 3 . We found the same results for MCT8 S194A in MDCK1 cells (unpublished data). Thus, hydrogen bonds are not necessary at these amino acid positions. The corresponding amino acid in the highly homologous MCT10 is Ala90. Again, the mutation of MCT10 A90S in MDCK1 cells did not affect T 3 uptake activity (45) , leading to the assumption that neither the removal nor the introduction of hydrogen bonds is essential at this position. Phenylalanine might disturb transport simply by its increased size. Our homology model suggests that large hydrophobic residues are neighbors of both serine residues: Ile190 and Leu198 flank Ser194, and Ser290 is flanked by Phe287 and Leu294. Thus, the exchange of serine to phenylalanine might disturb the movement of helices mediated by substrates.
The current pharmacological treatment of AHDS follows the rationale of providing a thyromimetic drug that can enter cells independently of MCT8. Diiodothyropropionic acid is reported to normalize the serum parameters of thyroid hormone function and allow weight gain, but improvements in neurologic impairment remained difficult to assess (46) . TRIAC rescues the developmental defects in an Mct8/Oatp1c1-deficient mouse model and is currently under investigation in a clinical trial (ClinicalTrials.gov identifier, NCT02060474). NaPB improves protein expression in MCT8 mutants that not only affect transport activity but also protein stability and localization at the cell surface. To test for the effects of NaPB on pathogenic MCT8, a good cell model is needed. Patient-derived fibroblasts are easy to obtain and culture. Nevertheless, the expression of MCT8 is very low, and the importance of MCT8 for the physiological function of skin fibroblasts is unclear. Although transcriptional profiling of patient-derived fibroblasts compared with control fibroblasts revealed differences in gene expression (47) , clinical symptoms such as the myxedematous skin changes found in patients with congenital hypothyroidism have not been reported in MCT8-deficient patients (48) . The effect of NaPB treatment on endogenous MCT8 expressed in primary human fibroblasts was modest. In contrast, NaPB significantly increased expression of pathogenic and wild-type MCT8 protein in overexpressing fibroblast-like COS7 cells, which are of primate origin. We thus do not believe that the response of pathogenic MCT8 mutants to NaPB is specific for the canine genetic background of MDCK1 cells. In general, the efficiency of protein insertion into the plasma membrane is low. In COS7 cells, it has been shown that only 20% to 25% of translated CFTR protein reaches the plasma membrane (49, 50) . Stabilization of unstable membrane proteins by chemical chaperones might be more important in cells expressing membrane proteins at high levels, and the low expression of MCT8 in human skin fibroblasts might not saturate the system. Thus, patient-derived fibroblasts might not be the best model to test for an ex vivo effect of NaPB, considering that MCT8 expression is much higher in the kidney, liver, thyroid, pituitary gland, and brain. However, nevertheless, because NaPB is safe for humans, it might represent an alternative to TRIAC or diiodothyropropionic acid treatment in the future for a subset of patients carrying responsive mutations. 
